About: Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases
Creator	Pawar, Ashish Affiliations, Ahire Deelip, Vishram Deepak, Devidas Derle, Derle, Yogesh Devidas Sonawane, Deepak Hiray, Apoorva Prashant Hiray, Apoorva Sonawane, Rajendra Sudhakar Bhambar, Sudhakar Bhambar, Rajendra Suresh Ahire, Suresh, Yogesh Yashwantrao Pawar, Ashish Yashwantrao, Ashish
Source	Elsevier; Medline; PMC
abstract	BACKGROUND & AIM: As on date, no specific treatment is available for devastating COVID-19 (SARS-CoV-2) infection. This pandemic viral infection has affected over 200 countries within a very short time and created a calamitous situationacross the globe. As per WHO guidelines, the treatment is mainly symptomatic andsupportive. This clinical protocol has not proven sufficient to save the lives of COVID-19 patients suffering from diabetes or having underlying liver diseases; hence there isutmost need to tackle this situation by other means such as Convalescent Plasma (CP)therapy. METHODS: A comprehensive literature survey was carriedout using Elsevier, PubMed, Taylor & Francis, Springer, Nature and Google searchengines. RESULTS: The patients suffering from diabetes or liverdysfunction or any other underlying diseases are at greatest risk of SARS-CoV-2infection. From the study, it is proved that plasma collected from the recovered patientsof viral infection has considerable potential to treat the viral disease without theoccurrence of adverse effects. CONCLUSION: The CP therapy can bea possible life saving alternative to treat critical COVID-19 patients having diabetes orunderlying liver dysfunction. Hence, randomised clinical trials are recommended at theearliest to save the lives of infected individuals of COVID-19.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.1016/j.dsx.2020.05.023
bibo:pmid	32438330
has license	no-cc
sha1sum (hex)	3d795c662b4fe8a4c38dacc1a3f84546409fcfdb
schema:url	https://doi.org/10.1016/j.dsx.2020.05.023
resource representing a document's title	Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases
has PubMed Central identifier	PMC7214325
has PubMed identifier	32438330
schema:publication	Diabetes Metab Syndr
resource representing a document's body	covid:3d795c662b4fe8a4c38dacc1a3f84546409fcfdb#body_text
is schema:about of	named entity 'protocol' named entity 'suffering' named entity 'COVID-19' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'CoV' named entity 'serum' named entity 'SARS' named entity 'convalescent plasma' named entity 'infection' named entity 'diabetes' named entity 'cholangiocytes' named entity 'H1N1' named entity 'host cell' named entity 'Ebola virus disease' named entity 'diabetes' named entity 'viral diseases' named entity 'chills' named entity 'China' named entity 'diabetes' named entity 'viral entry' named entity 'DCGI' named entity 'diabetes' named entity 'nausea' named entity 'SARS' named entity 'transfusion' named entity 'clinical studies' named entity 'infection' named entity 'convalescent plasma' named entity 'Neutralizing antibodies' named entity 'plasma' named entity 'H1N1' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'haemoglobin' named entity 'diabetes' named entity 'antibodies' named entity 'viral infections' named entity 'cell entry' named entity 'SARS-CoV-2' named entity 'China' named entity 'diabetes' named entity 'successful treatment' named entity 'Remdesivir' named entity 'adverse effects' named entity 'India' named entity 'Hubei province' named entity 'Coronavirus disease 2019' named entity 'infection' named entity 'itching' named entity 'International Diabetes Federation' named entity 'mortality rate' named entity 'University of Oxford' named entity 'liver cells' named entity 'China' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'viral replication' named entity 'virus' named entity 'search engines' named entity 'receptor binding domain' named entity 'viral strain' named entity 'convalescent plasma' named entity 'body temperature' named entity 'convalescent plasma' named entity 'single-stranded'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software